Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics Inc. leadership overhyped prospects for three neurological and psychiatric treatments, harming the biopharmaceutical company’s repute and wallet, a shareholder lawsuit said.

Sales are likely to have improved sequentially in the first quarter. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses for the ...

Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen ... remains ongoing Sage Therapeutics, Inc ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors. In terms of prescriber ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.